Online inquiry

IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13740MR)

This product GTTS-WQ13740MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPTL3 gene. The antibody can be applied in Hypertriglyceridemia&Homozygous familial hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014495.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27329
UniProt ID Q9Y5C1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13740MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9433MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ10661MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ45MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ4494MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ13722MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ11211MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ11447MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ913MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW